Patent application number | Description | Published |
20090048183 | IAP BINDING COMPOUNDS - IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K | 02-19-2009 |
20100056495 | DIMERIC IAP INHIBITORS - Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases. | 03-04-2010 |
20100075911 | DIMERIC IAP INHIBITORS - Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language | 03-25-2010 |
20100113326 | DIMERIC IAP INHIBITORS - Compounds made up of a homodimer or heterodimer having monomeric units of formula (I): wherein: each A is, independently, NR | 05-06-2010 |
20100143499 | DIMERIC IAP INHIBITORS - Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases. | 06-10-2010 |
20100144650 | DIMERIC IAP INHIBITORS - Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases. | 06-10-2010 |
20110003877 | SMAC Mimetic - A SMAC mimetic and pharmaceutical compositions thereof and methods of use. | 01-06-2011 |
20110237517 | IAP INHIBITORS - The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. | 09-29-2011 |
20110294827 | IAP BINDING COMPOUNDS - IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K | 12-01-2011 |
20110301151 | DIMERIC IAP INHIBITORS - Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language | 12-08-2011 |
20110305777 | DIMERIC IAP ANTAGONISTS - Smac mimetics that inhibit IAPs. | 12-15-2011 |
20120157390 | IAP Inhibitors - Smac mimetics that inhibit IAPs. | 06-21-2012 |
20120184530 | Dimeric IAP Inhibitors - Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases. | 07-19-2012 |
20130012564 | SMAC Mimetic - A SMAC mimetic and pharmaceutical compositions thereof and methods of use. | 01-10-2013 |
20130289042 | DIMERIC IAP INHIBITORS - Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language | 10-31-2013 |
20130289075 | IAP BINDING COMPOUNDS - IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPB (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K | 10-31-2013 |
20140073579 | SMAC Mimetic - A SMAC mimetic and pharmaceutical compositions thereof and methods of use. | 03-13-2014 |
20140303090 | Smac Mimetic Therapy - A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes. | 10-09-2014 |
20140329823 | Dimeric IAP Inhibitors - Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language | 11-06-2014 |